Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 1065-1073

  Millward, Michael ^a   Mainwaring, Paul ^b,e   Mita, Alain ^c   Federico, Kristine ^d   Lloyd, G K ^d   Reddinger, Natasha ^d   Nawrocki, Steffan ^c   Mita, Monica ^c   Spear, Matthew A ^d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Mater Hospital   (Australia)

^c CTRC Institute for Drug Development   (United States)

^d Nereus Pharmaceuticals Inc   (United States)

^e Haematology and Oncology Clinics of Australia   (Australia)

Author keywords

Angiogenesis; Docetaxel; Non small cell lung cancer (NSCLC); Vascular disrupting agent (VDA); Vascular targeting

Indexed keywords

DOCETAXEL; PLINABULIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPOMAGNESEMIA; INFECTION; LEG EDEMA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; DIKETOPIPERAZINES; FATIGUE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PAIN; TAXOIDS; VOMITING;

EID: 84864349509     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9642-4     Document Type: Article

References (27)

1. Denekamp J (1982) Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45:136-9 (Pubitemid 12207761)
2. Denekamp J (1991) The current status of targeting tumour vasculature as a means of cancer therapy: an overview. Int J Radiat Biol 60:401-8
3. Kakolyris S, Fox SB, Koukourakis M et al (2000) Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. Br J Cancer 85:844-51 (Pubitemid 30085237)
4. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134 (Pubitemid 46089673)
5. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus Interferon Alfa in metastatic renal cellcarcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
6. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-Carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
7. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizu-mab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-42 (Pubitemid 38702844)
8. Ramaswamy B, Elias AD, Kelbick NT et al (2006) Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 10:3124-29 (Pubitemid 43837360)
9. Keating GM, Santoro A (2009) Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69:223-240
10. Nathan PD, Judson I, Padhani A et al (2008) A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 26 Suppl. (Abstr 3550).
11. Siemann DW, Shi W (2008) Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 28:2027-31
12. Shi W, Siemann DW (2005) Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 19:1045-50 (Pubitemid 41631508)
13. A Study to Assess the Effectiveness of the Combination of Carboplatin, Paclitaxel, Bevacizumab and Combretastatin (CA4P) in Patients With Chemotherapy Naïve Lung Cancer. http://www. clinicaltrials.gov/ct2/show/NCT00653939
14. McKeage MJ, Von Pawel J, Reck M et al (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 99:2006-12
15. Rustin GJS, Galbraith SM, Anderson H et al (2003) Phase I clinical trial of weekly combretastatin a4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:2815-22 (Pubitemid 46621828)
16. Beerepoot LV, Radema SA, Witteveen EO et al (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-98 (Pubitemid 46638769)
17. Vamsidhar V, Avinash V, Ramaswamy G (2006) The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with Bevacizumab: a single institutional survey. Journal ofThoracic Oncol 1(5):501
18. Scagliotti GV, Park K, Patil S et al (2009) Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer 45(13):2298-2303
19. Nicholson B, Lloyd GK, Miller BR et al (2006) NPI-2358 is a tubulin-depolymerizing agent: In-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 17:25-31
20. Mita M, Spear MA, Yee LK et al (2010) Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res 16 (23):5892-9
21. Lloyd GK, Nicholson B, Neuteboom STC et al (2003) NPI-2358: A new vascular/tubulin modifying agent greatly poten-tiates standard chemotherapy in xenograft models. EORTC-NCI-AACR Molecular Targets and Therapeutics Meeting, Boston, MA
22. Neuteboom STC, Medina E, Palladino MA et al (2008) NPI-2358, A novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV522. Eur J Cancer 6 Suppl. (Abstr 141). Taxotere (docetaxel) Prescribing Information (2007) Sanofi-Aventis
23. LoRusso PM, Jones SF, Koch KM et al (2008) Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 26:3051-6
24. Heist R, Aren O, Millward M et al (2009) Phase 1/2 study of the vascular disrupting agent (VDA) plinabulin (NPI-2358) combined with docetaxel in patients with non-small cell lung cancer (NSCLC). Mol Cancer Ther 8 Suppl. (Abstr C30)
25. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103 (Pubitemid 30324363)
26. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-97 (Pubitemid 41079796)
27. Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer. http://www.clinicaltrials. gov/ct2/show/NCT00630110